cdmo.directory
Home
Cell-Easy logo

Cell-Easy

Cell therapy CDMO specializing in process development, analytical assays, GMP cell banking, and clinical-scale manufacturing.

Cell-Easy is a CDMO specializing in development and GMP manufacturing of cell therapies, with expertise across T cells, NK cells, MSCs, and iPSCs. The company has manufactured over 1,000 clinical doses and supports 50+ development programs from process optimization through regulatory compliance. Headquartered in Toulouse, France.

Modalities

Development & manufacturing

Structured CDMO capabilities from verified public sources.

Regulatory clearances

Services

Indications

About this organization

Overview

Cell-Easy is a dedicated cell therapy CDMO founded in 2015, born from direct biotech development experience. The company focuses exclusively on cell therapy manufacturing, combining biology expertise, pharmaceutical know-how, and smart technologies to help academic laboratories, biotechs, and pharma companies overcome development and GMP challenges.

Core Services

  • Process Diagnostic & Development: Process development, optimization, and scale-up for cell therapy manufacturing
  • Analytical Development: Analytical assay and potency test development
  • GMP Cell Banking: Establishment and maintenance of GMP-grade cell banks
  • GMP Manufacturing: Full-scale GMP production of cell therapy products

Modalities & Cell Types

Cell-Easy handles 15+ cell types including:

  • Immune cells: CAR-T, NK cells, T regulatory cells, non-engineered T cells
  • Stem cells: Mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs)
  • Immortalized cell lines

Experience spans both autologous and allogeneic therapies, engineered and non-engineered approaches, with applications in immuno-oncology and regenerative medicine.

Regulatory & Quality

The company operates with regulatory compliance at every stage, following ICH Q2 (R1), European Pharmacopeia, EMA/MHRA, and US Pharmacopeia standards. The team has a proven track record of successful regulatory audits and supports clients through the full path to clinic.

Track Record

  • 1,000+ clinical doses manufactured in GMP facility
  • 50+ active development programs
  • Recent clinical milestone: A-MUSE Phase 1/2 trial (allogeneic MSC platform in systemic sclerosis) launched with CHU Toulouse
  • €12M Bpifrance grant for iPSC-derived beta cell manufacturing platform
  • G-Rex® Grant recipient for European hub development

Locations

  • Headquarters

    Toulouse · Occitanie · France

Similar profiles by shared services, modalities, and capabilities.

Submit a verified review for this organization.

Markdown mirror: /companies/cell-easy.md